There is a lack of report of conscious sedation used as a last resort therapy for alleviating severe symptoms. To achieve this goal, dexmedetomidine appears to be a promising option. We report a case of successful two-month long treatment of intravenous (IV) dexmedetomidine added to hydromorphone for intractable cancer pain, restlessness, severe sleep disorder, anxiety, and craving symptoms in a 40-year-old man with active polysubstance use, receiving escalating doses of opioids for intractable abdominal cancer pain together with benzodiazepines. Under dexmedetomidine infusion at 1.2 μg/kg/hour, his symptoms markedly decreased. He could sleep at night and find respite during the day while continuing walking, eating, and other activities. Long-term conscious sedation with IV dexmedetomidine was well tolerated. We did not observe anxiety or agitation rebound during short periods of discontinuation of the infusion. Neither side effects nor tolerance were observed over time. Further research is needed to investigate the indications for conscious sedation and analgesia with dexmedetomidine in palliative patients with a prognosis that is longer than few weeks or uncertain.
Get full access to this article
View all access options for this article.
References
1.
ChernyNI, RadbruchL. Board of the European Association for Palliative Care. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med, 2009; 23(7):581–593; doi: 10.1177/0269216309107024
2.
SoaresLG, NaylorC, MartinsMA, et al.Dexmedetomidine: A new option for intractable distress in the dying. J Pain Symptom Manage, 2002; 24(1):6–8; doi: 10.1016/s0885-3924(02)00423-2
3.
KomasawaN, IkegakiJ. A case of dexmedetomidine administration for slight end-stage sedation in a patient with sudden continuous bleeding. Masui, 2014; 63(5):568–571.
4.
SeymoreRJ, ManisMM, CoynePJ. Dexmedetomidine use in a case of severe cancer pain. J Pain Palliat Care Pharmacother, 2019; 33(1–2):34–41; doi: 10.1080/15360288.2019.1629520
5.
HofherrML, AbrahmJL, RickersonE. Dexmedetomidine: A novel strategy for patients with intractable pain, opioid-induced hyperalgesia, or delirium at the end of life. J Palliat Med, 2020; 23(11):1515–1517; doi: 10.1089/jpm.2019.0427
6.
ThomasB, LoWA, NangatiZ, et al.Dexmedetomidine for hyperactive delirium at the end of life: An open-label single arm pilot study with dose escalation in adult patients admitted to an inpatient palliative care unit. Palliat Med, 2021; 35(4):729–737; doi: 10.1177/0269216321994440
7.
ByrneJM, MesarwiP, EdmondsKP, et al.Dexmedetomidine continuous infusion for refractory cancer pain at end of life: A case report. J Pain Palliat Care Pharmacother, 2022; 36(3):200–206; doi: 10.1080/15360288.2022.2102705
8.
VirtanenR, SavolaJM, SaanoV, et al.Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol, 1988; 150:9–14.
9.
ZhaoY, HeJ, YuN, et al.Mechanisms of dexmedetomidine in neuropathic pain. Front Neurosci, 2020; 14:330; doi: 10.3389/fnins.2020.00330
10.
HilliardN, BrownS, MitchinsonS. A case report of dexmedetomidine used to treat intractable pain and delirium in a tertiary palliative care unit. Palliat Med, 2015; 29(3):278–281; doi: 10.1177/0269216314556923
11.
BushSH, GrassauPA, YarmoMN, et al.The Richmond Agitation-Sedation Scale modified for palliative care inpatients (RASS-PAL): A pilot study exploring validity and feasibility in clinical practice. BMC Palliat Care, 2014; 13(1):17; doi: 10.1186/1472-684X-13-17
12.
WeissRD, GriffinML, MazurickC, et al.The relationship between cocaine craving, psychosocial treatment, and subsequent cocaine use. Am J Psychiatry, 2003; 160(7):1320–1325; doi: 10.1176/appi.ajp.160.7.1320
13.
McHughRK, TrinhCD, GriffinML, et al.Validation of the craving scale in a large sample of adults with substance use disorders. Addict Behav, 2021; 113:106651; doi: 10.1016/j.addbeh.2020.106651
14.
Campbell-SillsL, NormanSB, CraskeMG, et al.Validation of a brief measure of anxiety-related severity and impairment: The Overall Anxiety Severity and Impairment Scale (OASIS). J Affect Disord, 2009; 112(1–3):92–101; doi: 10.1016/j.jad.2008.03.014
15.
AbuhasnaS, Al JundiA, AbdelattyW, et al.Evaluation of long-term infusion of dexmedetomidine in critically ill patients: A retrospective analysis. Int J Crit Illn Inj Sci, 2012; 2(2):70–74; doi: 10.4103/2229-5151.97270
16.
MacLarenR, PreslaskiCR, MuellerSW, et al.A randomized, double-blind pilot study of dexmedetomidine versus midazolam for intensive care unit sedation: Patient recall of their experiences and short-term psychological outcomes. J Intensive Care Med, 2015; 30(3):167–175; doi: 10.1177/0885066613510874
17.
ReadeMC, EastwoodGM, BellomoR, et al.Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: A randomized clinical trial. JAMA, 2016; 315(14):1460–1468; doi: 10.1001/jama.2016.2707; Erratum in: JAMA 2016;316(7):775.
18.
SkrobikY, DupreyMS, HillNS, et al.Low-dose nocturnal dexmedetomidine prevents ICU delirium. A randomized, placebo-controlled trial. Am J Respir Crit Care Med, 2018; 197(9):1147–1156; doi: 10.1164/rccm.201710-1995OC
19.
ChenK, LuZ, XinYC, et al.Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. Cochrane Database Syst Rev, 2015; 1(1):CD010269; doi: 10.1002/14651858.CD010269.pub2
20.
ShehabiY, HoweBD, BellomoR, et al.Early sedation with dexmedetomidine in critically ill patients. N Engl J Med, 2019; 380(26):2506–2517; doi: 10.1056/NEJMoa1904710
21.
SmuszkiewiczP, WiczlingP, BerJ, et al.Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients. J Pharmacokinet Pharmacodyn, 2018; 45(2):277–284; doi: 10.1007/s10928-017-9564-7
22.
IirolaT, IhmsenH, LaitioR, et al.Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients. Br J Anaesth, 2012; 108(3):460–468; doi: 10.1093/bja/aer441
23.
TobiasJD, BerkenboschJW. Sedation during mechanical ventilation in infants and children: Dexmedetomidine versus midazolam. South Med J, 2004; 97:451–455.
24.
WhalenLD, Di GennaroJL, GretchenAI, et al.Long-term dexmedetomidine use and safety profile among critically ill children and neonates. Pediatr Crit Care Med, 2014; 15(8):706–714; doi: 10.1097/PCC.0000000000000200
25.
EnomotoY, KudoT, SaitoT, et al.Prolonged use of dexmedetomidine in an infant with respiratory failure following living donor liver transplantation. Paediatr Anaesth, 2006; 16:1285–1288.
26.
FergusonL, HooperS. Dexmedetomidine withdrawal syndrome and opioid sensitivity. BMJ Support Palliat Care, 2020; doi: 10.1136/bmjspcare-2020-002705
27.
OzakiM, TakedaJ, TanakaK, et al.Safety and efficacy of dexmedetomidine for long-term sedation in critically ill patients. J Anesth, 2014; 28(1):38–50; doi: 10.1007/s00540-013-1678-5
28.
FliellerLA, AlanizC, PlevaMR, et al.Incidence of rebound hypertension after discontinuation of dexmedetomidine. Pharmacotherapy, 2019; 39(10):970–974; doi: 10.1002/phar.2323
29.
WeerinkMAS, StruysMMRF, HannivoortLN, et al.Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet, 2017; 56(8):893–913; doi: 10.1007/s40262-017-0507-7
30.
KaurM, SinghPM. Current role of dexmedetomidine in clinical anesthesia and intensive care. Anesth Essays Res, 2011; 5(2):128–133; doi: 10.4103/0259-1162.94750
31.
FannonS, KistingMA, AndersonC. Implementation of a protocol: Dexmedetomidine for use in long-term procedural sedation in non-intubated pediatric patients. J Pediatr Nurs, 2021; 58:39–43; doi: 10.1016/j.pedn.2020.11.005
32.
WolfeA, ZhangJ, LapenskieJ, et al.Stability of dexmedetomidine in polyvinyl chloride bags containing 0.9% sodium chloride intended for subcutaneous infusions. Int J Pharm Compd, 2021; 25(4):330–335.
33.
UusaloP, Al-RamahiD, TilliI, et al.Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers. Eur J Clin Pharmacol, 2018; 74(8):1047–1054; doi: 10.1007/s00228-018-2461-1
34.
ThomasB, MurrellL, SpendleyP. Dexmedetomidine: Admixture compatibility with palliative care drugs. BMJ Support Palliat Care, 2021; doi: 10.1136/bmjspcare-2020-002583
35.
Dexmedetomidine for Sedation in the ICU orPICU. A Review of Cost-Effectiveness and Guidelines [Internet]. Canadian Agency for Drugs and Technologies in Health: Ottawa, ON; 2014.
36.
AggarwalJ, LustrinoJ, StephensJ, et al.Cost-minimization analysis of dexmedetomidine compared to other sedatives for short-term sedation during mechanical ventilation in the United States. Clinicoecon Outcomes Res, 2020; 12:389–397; doi: 10.2147/CEOR.S242994; Erratum in: Clinicoecon Outcomes Res 2020;12:619–623.
37.
SongHN, LeeUS, LeeGW, et al.Long-term intermittent palliative sedation for refractory symptoms at the end of life in two cancer patients. J Palliat Med, 2015; 18(9):807–810; doi: 10.1089/jpm.2014.0357
38.
JobesML, GhitzaUE, EpsteinDH, et al.Clonidine blocks stress-induced craving in cocaine users. Psychopharmacology (Berl), 2011; 218(1):83–88; doi: 10.1007/s00213-011-2230-7
39.
GiovannittiJAJr., ThomsSM, CrawfordJJ.Alpha-2 adrenergic receptor agonists: A review of current clinical applications. Anesth Prog, 2015; 62(1):31–39; doi: 10.2344/0003-3006-62.1.31
40.
RileyDS, BarberMS, KienleGS, et al.CARE guidelines for case reports: Explanation and elaboration document. J Clin Epidemiol, 2017; 89:218–235; doi: 10.1016/j.jclinepi.2017.04.026
